Page last updated: 2024-12-06

2,3-dihydroxypyridine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2,3-Dihydroxypyridine, also known as 2,3-pyridinediol, is a heterocyclic compound with two hydroxyl groups attached to the pyridine ring. It is a white crystalline solid. It is a versatile building block for the synthesis of various pharmaceutical and agricultural chemicals. It has been shown to possess antibacterial, antifungal, and antioxidant properties. Studies have explored its potential as a precursor for synthesizing other bioactive compounds. Its structural features and potential biological activities make it an interesting target for research.'

2,3-dihydroxypyridine: affects thyroid function [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

pyridine-2,3-diol : A dihydroxypyridine in which the two hydroxy groups are located at positions 2 and 3. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID28115
CHEMBL ID287899
CHEBI ID131454
SCHEMBL ID82455
MeSH IDM0109676

Synonyms (66)

Synonym
AC-4671
einecs 240-887-3
ai3-61776
nsc 49272
3-hydroxy-2-pyridone
3-hydroxy-2(1h)-pyridinone
STL352048
2(1h)-pyridone, 3-hydroxy-
nsc-49272
2,3-pyridinediol
16867-04-2
pyridine-2,3-diol
2,3-dihydroxypyridine
nsc49272
2,3-dhbeeop
AC-907/25014062
inchi=1/c5h5no2/c7-4-2-1-3-6-5(4)8/h1-3,7h,(h,6,8
3-hydroxypyridin-2(1h)-one
2(1h)-pyridinone, 3-hydroxy-
2,3-dihydroxypyridine, 95%
2,3-dihydroxy-pyridine
E8AC675C-AD76-443C-923D-97F94E3ACAD0
CHEMBL287899 ,
ksc-11-228-5
KUC106761N
P0755
3-hydroxy-1h-pyridin-2-one
CHEBI:131454
AKOS000121284
A811001
3-oxidanyl-1h-pyridin-2-one
A840898
AKOS005257646
84719-32-4
7hy4bcj130 ,
unii-7hy4bcj130
bdbm50431088
8lg ,
FT-0646597
FT-0609672
dihydroxypyridine, 2,3-
SCHEMBL82455
BBL027572
hydroxy pyridone
hydroxypyridone
dihydroxypyridine
NCGC00357054-01
cas-16867-04-2
dtxcid9030337
dtxsid0051782 ,
tox21_303751
W-107899
3-hydroxy-2(1h)-pyridone
mfcd00006271
CS-W009004
3-hydroxy-2-pyridinone
3-hydroxy-1,2-dihydropyridin-2-one
P19753
F0001-0615
SY015232
AMY21893
Q27225138
SB52507
EN300-21327
2,3-dihydroxy pyridine
Z104495360

Research Excerpts

Toxicity

ExcerptReferenceRelevance
"Cattle and goats in Australia lack the ability to totally degrade 3-hydroxy-4(1H)-pyridone, also known as 3,4-dihydroxy pyridine (3,4 DHP), the ruminal metabolite of mimosine, a toxic aminoacid present in the leguminous shrub Leucaena leucocephala."( Successful transfer of DHP-degrading bacteria from Hawaiian goats to Australian ruminants to overcome the toxicity of Leucaena.
Jones, RJ; Megarrity, RG, 1986
)
0.27

Dosage Studied

ExcerptRelevanceReference
" In another experiment, oral dosing of eight Angora bucks (23+/-."( Effects of mimosine and 2,3-dihydroxypyridine on fiber shedding in Angora goats.
Goetsch, AL; Puchala, R; Reis, PJ; Sahlu, T, 1999
)
0.61
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
dihydroxypyridine
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
nicotine degradation I (pyridine pathway)1341

Protein Targets (4)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency64.86010.001022.650876.6163AID1224838; AID1224893
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency19.33120.001530.607315,848.9004AID1224848; AID1224849; AID1259403
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
D-amino-acid oxidaseHomo sapiens (human)IC50 (µMol)1.15000.00401.119910.0000AID735291
Histone deacetylase 1Homo sapiens (human)IC50 (µMol)0.02000.00010.55439.9000AID734736
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (50)

Processvia Protein(s)Taxonomy
proline catabolic processD-amino-acid oxidaseHomo sapiens (human)
digestionD-amino-acid oxidaseHomo sapiens (human)
D-amino acid catabolic processD-amino-acid oxidaseHomo sapiens (human)
D-serine catabolic processD-amino-acid oxidaseHomo sapiens (human)
dopamine biosynthetic processD-amino-acid oxidaseHomo sapiens (human)
D-alanine catabolic processD-amino-acid oxidaseHomo sapiens (human)
D-serine metabolic processD-amino-acid oxidaseHomo sapiens (human)
neutrophil-mediated killing of gram-negative bacteriumD-amino-acid oxidaseHomo sapiens (human)
negative regulation of myotube differentiationHistone deacetylase 1Homo sapiens (human)
negative regulation of apoptotic processHistone deacetylase 1Homo sapiens (human)
positive regulation of signaling receptor activityHistone deacetylase 1Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIHistone deacetylase 1Homo sapiens (human)
chromatin organizationHistone deacetylase 1Homo sapiens (human)
chromatin remodelingHistone deacetylase 1Homo sapiens (human)
DNA methylation-dependent heterochromatin formationHistone deacetylase 1Homo sapiens (human)
regulation of transcription by RNA polymerase IIHistone deacetylase 1Homo sapiens (human)
protein deacetylationHistone deacetylase 1Homo sapiens (human)
endoderm developmentHistone deacetylase 1Homo sapiens (human)
positive regulation of cell population proliferationHistone deacetylase 1Homo sapiens (human)
epidermal cell differentiationHistone deacetylase 1Homo sapiens (human)
positive regulation of gene expressionHistone deacetylase 1Homo sapiens (human)
negative regulation of gene expressionHistone deacetylase 1Homo sapiens (human)
hippocampus developmentHistone deacetylase 1Homo sapiens (human)
neuron differentiationHistone deacetylase 1Homo sapiens (human)
negative regulation of cell migrationHistone deacetylase 1Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayHistone deacetylase 1Homo sapiens (human)
circadian regulation of gene expressionHistone deacetylase 1Homo sapiens (human)
cellular response to platelet-derived growth factor stimulusHistone deacetylase 1Homo sapiens (human)
odontogenesis of dentin-containing toothHistone deacetylase 1Homo sapiens (human)
regulation of cell fate specificationHistone deacetylase 1Homo sapiens (human)
embryonic digit morphogenesisHistone deacetylase 1Homo sapiens (human)
negative regulation of apoptotic processHistone deacetylase 1Homo sapiens (human)
negative regulation of canonical NF-kappaB signal transductionHistone deacetylase 1Homo sapiens (human)
negative regulation by host of viral transcriptionHistone deacetylase 1Homo sapiens (human)
negative regulation of gene expression, epigeneticHistone deacetylase 1Homo sapiens (human)
negative regulation of DNA-templated transcriptionHistone deacetylase 1Homo sapiens (human)
positive regulation of DNA-templated transcriptionHistone deacetylase 1Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIHistone deacetylase 1Homo sapiens (human)
positive regulation of smooth muscle cell proliferationHistone deacetylase 1Homo sapiens (human)
oligodendrocyte differentiationHistone deacetylase 1Homo sapiens (human)
positive regulation of oligodendrocyte differentiationHistone deacetylase 1Homo sapiens (human)
negative regulation of androgen receptor signaling pathwayHistone deacetylase 1Homo sapiens (human)
hair follicle placode formationHistone deacetylase 1Homo sapiens (human)
eyelid development in camera-type eyeHistone deacetylase 1Homo sapiens (human)
fungiform papilla formationHistone deacetylase 1Homo sapiens (human)
negative regulation of canonical Wnt signaling pathwayHistone deacetylase 1Homo sapiens (human)
negative regulation of stem cell population maintenanceHistone deacetylase 1Homo sapiens (human)
positive regulation of stem cell population maintenanceHistone deacetylase 1Homo sapiens (human)
regulation of stem cell differentiationHistone deacetylase 1Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathwayHistone deacetylase 1Homo sapiens (human)
heterochromatin formationHistone deacetylase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (22)

Processvia Protein(s)Taxonomy
D-amino-acid oxidase activityD-amino-acid oxidaseHomo sapiens (human)
protein bindingD-amino-acid oxidaseHomo sapiens (human)
identical protein bindingD-amino-acid oxidaseHomo sapiens (human)
FAD bindingD-amino-acid oxidaseHomo sapiens (human)
nucleosomal DNA bindingHistone deacetylase 1Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingHistone deacetylase 1Homo sapiens (human)
RNA polymerase II core promoter sequence-specific DNA bindingHistone deacetylase 1Homo sapiens (human)
core promoter sequence-specific DNA bindingHistone deacetylase 1Homo sapiens (human)
transcription corepressor bindingHistone deacetylase 1Homo sapiens (human)
p53 bindingHistone deacetylase 1Homo sapiens (human)
transcription corepressor activityHistone deacetylase 1Homo sapiens (human)
histone deacetylase activityHistone deacetylase 1Homo sapiens (human)
protein bindingHistone deacetylase 1Homo sapiens (human)
enzyme bindingHistone deacetylase 1Homo sapiens (human)
protein lysine deacetylase activityHistone deacetylase 1Homo sapiens (human)
Krueppel-associated box domain bindingHistone deacetylase 1Homo sapiens (human)
histone deacetylase bindingHistone deacetylase 1Homo sapiens (human)
NF-kappaB bindingHistone deacetylase 1Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingHistone deacetylase 1Homo sapiens (human)
E-box bindingHistone deacetylase 1Homo sapiens (human)
DNA-binding transcription factor bindingHistone deacetylase 1Homo sapiens (human)
histone decrotonylase activityHistone deacetylase 1Homo sapiens (human)
promoter-specific chromatin bindingHistone deacetylase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (17)

Processvia Protein(s)Taxonomy
mitochondrial outer membraneD-amino-acid oxidaseHomo sapiens (human)
extracellular regionD-amino-acid oxidaseHomo sapiens (human)
cytoplasmD-amino-acid oxidaseHomo sapiens (human)
peroxisomal matrixD-amino-acid oxidaseHomo sapiens (human)
cytosolD-amino-acid oxidaseHomo sapiens (human)
cell projectionD-amino-acid oxidaseHomo sapiens (human)
presynaptic active zoneD-amino-acid oxidaseHomo sapiens (human)
cytoplasmD-amino-acid oxidaseHomo sapiens (human)
nucleusHistone deacetylase 1Homo sapiens (human)
nucleoplasmHistone deacetylase 1Homo sapiens (human)
cytoplasmHistone deacetylase 1Homo sapiens (human)
cytosolHistone deacetylase 1Homo sapiens (human)
NuRD complexHistone deacetylase 1Homo sapiens (human)
neuronal cell bodyHistone deacetylase 1Homo sapiens (human)
Sin3-type complexHistone deacetylase 1Homo sapiens (human)
histone deacetylase complexHistone deacetylase 1Homo sapiens (human)
chromatinHistone deacetylase 1Homo sapiens (human)
heterochromatinHistone deacetylase 1Homo sapiens (human)
transcription repressor complexHistone deacetylase 1Homo sapiens (human)
protein-containing complexHistone deacetylase 1Homo sapiens (human)
nucleusHistone deacetylase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (21)

Assay IDTitleYearJournalArticle
AID734735Inhibition of HDAC8 (unknown origin) at 10 uM after 60 mins by SAMDI spectrophotometric analysis relative to control2013Journal of medicinal chemistry, May-09, Volume: 56, Issue:9
3-Hydroxypyridin-2-thione as novel zinc binding group for selective histone deacetylase inhibition.
AID566705Inhibition of human recombinant MMP8 at 1 mM after 30 mins2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID1165109Antileishmanial activity against amastigote stage of Leishmania donovani infected in human THP1 cells after 48 hrs by Alamar blue assay2014Bioorganic & medicinal chemistry letters, Oct-15, Volume: 24, Issue:20
The antileishmanial activity of isoforms 6- and 8-selective histone deacetylase inhibitors.
AID1165110Cytotoxicity against human THP1 cells after 48 hrs by Alamar blue assay2014Bioorganic & medicinal chemistry letters, Oct-15, Volume: 24, Issue:20
The antileishmanial activity of isoforms 6- and 8-selective histone deacetylase inhibitors.
AID735291Inhibition of human recombinant DAAO after 30 mins by plate reader analysis2013Journal of medicinal chemistry, May-09, Volume: 56, Issue:9
4-Hydroxypyridazin-3(2H)-one derivatives as novel D-amino acid oxidase inhibitors.
AID566703Inhibition of human recombinant MMP2 at 1 mM after 30 mins2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID314590Growth inhibition of Vibrio harveyi assessed as time required to double bacterial growth relative to control2008Bioorganic & medicinal chemistry letters, Mar-01, Volume: 18, Issue:5
Pyrogallol and its analogs can antagonize bacterial quorum sensing in Vibrio harveyi.
AID142203Compound was tested in vitro for its inhibitory activity against murine P-388 leukemia1984Journal of medicinal chemistry, Feb, Volume: 27, Issue:2
Synthesis of 3-hydroxy-2- and -4-pyridone nucleosides as potential antitumor agents.
AID734736Inhibition of HDAC1 (unknown origin) at 10 uM after 60 mins by SAMDI spectrophotometric analysis relative to control2013Journal of medicinal chemistry, May-09, Volume: 56, Issue:9
3-Hydroxypyridin-2-thione as novel zinc binding group for selective histone deacetylase inhibition.
AID566702Inhibition of human recombinant MMP1 at 1 mM after 30 mins2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID566707Inhibition of mouse recombinant iNOS at 1 mM after 40 mins by colorimetric assay2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID1165104Antileishmanial activity against promastigote stage of Leishmania donovani after 72 hrs by Alamar blue assay2014Bioorganic & medicinal chemistry letters, Oct-15, Volume: 24, Issue:20
The antileishmanial activity of isoforms 6- and 8-selective histone deacetylase inhibitors.
AID566700Inhibition of human recombinant 5-lipoxygenase at 1 mM after 10 mins by fluorescence assay2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID566699Inhibition of mushroom tyrosinase at 1 mM after 10 mins2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID735284Inhibition of DAAO (unknown origin) by cell based assay2013Journal of medicinal chemistry, May-09, Volume: 56, Issue:9
4-Hydroxypyridazin-3(2H)-one derivatives as novel D-amino acid oxidase inhibitors.
AID566704Inhibition of human recombinant MMP3 at 1 mM after 30 mins2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID566706Inhibition of human recombinant MMP9 at 1 mM after 30 mins2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID566701Inhibition of recombinant anthrax lethal factor at 1 mM after 30 mins by fluorescence assay2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID734737Inhibition of HDAC6 (unknown origin) at 10 uM after 60 mins by SAMDI spectrophotometric analysis relative to control2013Journal of medicinal chemistry, May-09, Volume: 56, Issue:9
3-Hydroxypyridin-2-thione as novel zinc binding group for selective histone deacetylase inhibition.
AID1165105Antileishmanial activity against axenic amastigote stage of Leishmania donovani after 72 hrs by Alamar blue assay2014Bioorganic & medicinal chemistry letters, Oct-15, Volume: 24, Issue:20
The antileishmanial activity of isoforms 6- and 8-selective histone deacetylase inhibitors.
AID735290Effective permeability of the compound at pH 6.5 after 2 hrs by PAMPA2013Journal of medicinal chemistry, May-09, Volume: 56, Issue:9
4-Hydroxypyridazin-3(2H)-one derivatives as novel D-amino acid oxidase inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (21)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (23.81)18.7374
1990's3 (14.29)18.2507
2000's5 (23.81)29.6817
2010's8 (38.10)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 22.12

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index22.12 (24.57)
Research Supply Index3.09 (2.92)
Research Growth Index4.62 (4.65)
Search Engine Demand Index21.17 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (22.12)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other21 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]